Literature DB >> 22669087

Nanomedicine: Downsizing tumour therapeutics.

Christopher J Cheng, W Mark Saltzman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22669087      PMCID： PMC7024603          DOI： 10.1038/nnano.2012.89

Source DB:  PubMed          Journal:  Nat Nanotechnol        ISSN： 1748-3387            Impact factor:   39.213


× No keyword cloud information.
  7 in total

Review 1.  Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors:  Sean T Duggan; Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

Authors:  Jun Fang; Hideaki Nakamura; Hiroshi Maeda
Journal:  Adv Drug Deliv Rev       Date:  2010-05-02       Impact factor: 15.470

Review 3.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

Review 4.  Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Authors:  Frank Alexis; Eric Pridgen; Linda K Molnar; Omid C Farokhzad
Journal:  Mol Pharm       Date:  2008-08-04       Impact factor: 4.939

Review 5.  Targeting of drugs and nanoparticles to tumors.

Authors:  Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  J Cell Biol       Date:  2010-03-15       Impact factor: 10.539

6.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

7.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner.

Authors:  Vikash P Chauhan; Triantafyllos Stylianopoulos; John D Martin; Zoran Popović; Ou Chen; Walid S Kamoun; Moungi G Bawendi; Dai Fukumura; Rakesh K Jain
Journal:  Nat Nanotechnol       Date:  2012-04-08       Impact factor: 39.213
  7 in total
  5 in total

1.  PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.

Authors:  Zhihang Chen; Marie-France Penet; Balaji Krishnamachary; Sangeeta R Banerjee; Martin G Pomper; Zaver M Bhujwalla
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

2.  Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization.

Authors:  Jill M Steinbach; Young-Eun Seo; W Mark Saltzman
Journal:  Acta Biomater       Date:  2015-11-18       Impact factor: 8.947

3.  Computationally guided high-throughput design of self-assembling drug nanoparticles.

Authors:  Daniel Reker; Yulia Rybakova; Ameya R Kirtane; Ruonan Cao; Jee Won Yang; Natsuda Navamajiti; Apolonia Gardner; Rosanna M Zhang; Tina Esfandiary; Johanna L'Heureux; Thomas von Erlach; Elena M Smekalova; Dominique Leboeuf; Kaitlyn Hess; Aaron Lopes; Jaimie Rogner; Joy Collins; Siddartha M Tamang; Keiko Ishida; Paul Chamberlain; DongSoo Yun; Abigail Lytton-Jean; Christian K Soule; Jaime H Cheah; Alison M Hayward; Robert Langer; Giovanni Traverso
Journal:  Nat Nanotechnol       Date:  2021-03-25       Impact factor: 40.523

4.  Lipid nanotechnology.

Authors:  Samaneh Mashaghi; Tayebeh Jadidi; Gijsje Koenderink; Alireza Mashaghi
Journal:  Int J Mol Sci       Date:  2013-02-21       Impact factor: 5.923

Review 5.  Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.

Authors:  Huanrong Lan; Wei Zhang; Ketao Jin; Yuyao Liu; Zhen Wang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.